Cogent Biosciences, Inc. COGT
- CGT4859 — Cholangiocarcinoma Phase 1
FGFR2 (3 companies · 3 programs)
Companies with an active program directed at FGFR2.
Relay Therapeutics, Inc. RLAY
- lirafugratinib — Cholangiocarcinoma NDA Submitted
Tyra Biosciences, Inc. TYRA
- TYRA-200 — Intrahepatic Cholangiocarcinoma Phase 1